Analysis of novel apolipoprotein B mutations using a modified U937 cell line LDL binding assay

Clinica Chimica Acta

Volumn 256, Issue 1, 1996, Pages 27-36

  Meng, Qing He ^a   Pajukanta, Päivi ^a   Ilmonen, Marja ^a   Schuster, H ^b   Schewe, C K ^c   Andersson, Leif C ^a   Tikkanen, Matti J ^a,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FRANZ VOLHARD CLINIC   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

apoB gene; Hypercholesterolemia; Low density lipoprotein; U937

Indexed keywords

APOLIPOPROTEIN B100;

ARTICLE; BIOASSAY; BLOOD ANALYSIS; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; ISOTOPE LABELING; LIPID ANALYSIS; MALE; MUTATION; PRIORITY JOURNAL; TECHNIQUE;

ALLELES; APOLIPOPROTEINS B; BIOCHEMISTRY; FEMALE; HUMANS; LIPOPROTEINS, LDL; LYMPHOMA, LARGE-CELL; MALE; MUTATION; PROTEIN BINDING; TUMOR CELLS, CULTURED;

EID: 0030577468     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(96)06409-1     Document Type: Article

References (22)

1. [1] Brown M, Kovanen P, Goldstein J. Regulation of plasma cholesterol by lipoprotein receptors. Science 1981;212:628-635.
2. [2] Innerarity T, Weisgraber K, Arnold K, Mahley R, Krauss R, Vega G, Grundy S. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 1987;84:6919-6923.
3. [3] Soria LF, Ludwig EH, Clarke HRG, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci 1989;86:587-591.
4. [4] Gaffney D, Reid JM, Cameron IM, Vass K, Caslake MJ, Shepherd J, Packard CJ. Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia. Arterioscler Thromb Vasc Biol 1995;15:1025-1029.
5. [5] Pullinger CR, Hennessy LK, Chatterton JE et al. Familial ligand-defective apolipoprotein B: identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest 1995;95:1225-1234.
6. [6] Hämäläinen T, Palotie A, Aalto-Selälä K, Kontula K, Tikkanen MJ. Absence of familial defective apolipoprotein B-100 in Finnish patients with elevated serum cholesterol. Atherosclerosis 1990;82:177-183.
7. [7] Ilmonen M, Heliö T, Bütler R, Palotie A, Pietinen P, Huttunen JK, Tikkanen MJ. Two new immunogenetic polymorphisms of the apolipoprotein B gene and their effect on serum lipid levels and responses to change in dietary fat intake. Arterioscler Thromb Vasc Biol 1995;15(9):1287-1293.
8. [8] Frostegård J, Hamsten A, Gidlund M, Nilsson J. Low density lipoprotein - induced growth of U937 cells: a novel method to determine the receptor binding of low density lipoprotein. J Lipid Res 1990;31:37-44.
9. [9] Sundström C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U937). Int J Cancer 1976;17:565-577.
10. [10] Esfahani M, Scerbo L, Devlin T. A requirement for cholesterol and its structural features for a human macrophage-like cell line. J Cell Biochem 1984;25:87-97.
11. [11] Schewe CK, Schuster H, Hailer S, Wolfram G, Keller C, Zöller N. Identification of defective binding of low density lipoprotein by the U937 proliferation assay in German patients with familial defective apolipoprotein B-100. Eur J Clin Invest 1994;24:36-41.
12. [12] Van den Broek AJCM, Hollaar L, Schaefer HIMB et al. Screening for familial defective apolipoprotein B-100 with improved U937 monocyte proliferation assay. Clin Chem 1994;40/3:395-399.
13. [13] Havel R, Eder H, Bragdon J. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-1353.
14. [14] Weisgraber KH, Innerarity TL, Mahley RW. Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J Biol Chem 1978;253:9053-9062.
15. [15] Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
16. [16] Bilheimer JT, Chamoun D, Esfahani M. Defective 3-ketosteroid reductase activity in a human monocyte-like cell line. J Lipid Res 1987;28:704-709.
17. [17] Weisgraber KH, Innerarity TL, Newhouse YM et al. Familial defective apolipoprotein B-100: Enhanced binding of monoclonal antibody MB47 to abnormal low density lipoproteins. Proc Natl Acad Sci 1988;85:9758-9762.
18. [18] Myant MB, Gallagher JJ, Knight BL et al. Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function. Arteriosclerosis Thromb 1991;11:691-703.
19. [19] Dunning AM, Houlston R, Frostegård J et al. Genetic evidence that the putative receptor binding domain of apolipoprotein B (residues 3130 to 3630) is not the only region of the protein involved in the interaction with the low density lipoprotein receptor. Biochim Biophys Acta 1991;1096:231-237.
20. [20] Fantappiè S, Corsini A, Sidoli A et al. Monoclonal antibodies to human low density lipoprotein identify distinct areas on apolipoprotein B-100 relevant to the low density lipoprotein-receptor interaction. J Lipid Res 1992;33:1111-1121.
21. [21] Talmud P, Barni N, Kessling A et al. Apolipoprotein B gene variants are involved in the determination of serum cholesterol levels: a study in normo-and hyperlipidaemic individuals. Atherosclerosis 1987;67:81-89.
22. [22] Chatterton JE, Phillips ML, Curtiss LK, Milne R, Fruchart JC, Schumaker VN. Immunoelectron microscopy of low density lipoproteins yields a ribbon and bow model for the conformation of apolipoprotein B on the lipoprotein surface. J Lipid Res 1995;36:2027-2037.